MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - December 08, 2011) -
MorphoSys AG /
MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated
phase 2 clinical trial in psoriasis patients with the HuCAL-derived
CNTO 1959. The event triggered a clinical milestone payment to MorphoSys.
Further financial details were not disclosed.
"With every clinical milestone and every new phase 2 start the time where
first HuCAL-based antibody drug could enter the market gets closer.
antibody pipeline has substantially matured over the last 18 months,"
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
In total, MorphoSys's clinical pipeline now comprises nine partnered
phase 1 and seven in phase 2 development as well as the Company's
programs MOR103, which is in a phase 1b/2a trial for rheumatoid
MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and
which is in a phase 1/2a trial for multiple myeloma.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
arYla(®), CysDisplay(®) and
RapMAT(®) are registered trademarks of MorphoSys AG.
Ylanthia(®) and 100 billion high potentials™ are trademarks of
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.